Chonluten
also known as bronchial bioregulator, respiratory peptide complex
Khavinson-school bioregulatory peptide complex targeting bronchial mucosa and respiratory epithelium. Preclinical data demonstrate modulation of proliferative activity and inflammatory pathways in monocyte/macrophage cell lines. Part of the Russian bioregulator tradition with tissue-specific organ peptide architecture. Limited Western research indexing; mechanistic evidence from in vitro models. [avolio-2022]
- Class
- Bioregulatory Peptide
- Evidence level
- Mechanistic animal evidence
- Regulatory status
- Not FDA-approved (US) — research use only
At a glance
Oral · Sublingual · Per Protocol
Primary target — Bronchial epithelial cells and respiratory mucosa tissue complexes.
Pathway — Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populations [avolio-2022].
Downstream effect — Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cells [avolio-2022].
Origin — Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology.
| Parameter | Value |
|---|---|
| Typical protocol dose | 10–20 mg / dayRussian bioregulator tradition dosing; not standardized in Western literature. |
| Frequency | Once or twice daily |
| Route | Oral (capsule) or sublingualSublingual claimed for enhanced bioavailability; not validated. |
| Evidence basis | In vitro mechanistic |
| Duration | 10–30 days per cycleTraditional Khavinson protocol; cyclic administration common. |
| Clinical validation | None (PubMed indexed) |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
- — Known hypersensitivity to peptide components
- — Pregnancy and lactation (insufficient data)
- — Active malignancy (theoretical bioregulator concern)
- 01Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
- 02Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
- 03Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
- 04Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
- 05Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
Frequently asked
Is Chonluten FDA-approved?
Chonluten is not FDA-approved in the United States and is handled as a research compound (research use only). Regulatory status may differ in other jurisdictions.
Sources
of 38 rendered claims carry a resolvable citation.
- [avolio-2022]Avolio 2022 — Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
journal, 2022